Biocon Refutes Graft Charges After Regulatory Official Booked, Says Due Process Followed

Expert Panel Trial Waiver Endorsement Came In May

Indian investigating agency probes alleged bribe paid to drugs regulator in a case pertaining to the approval process of Biocon Biologics’ insulin aspart. The company strongly denies the allegations, underscoring that all its product approvals are backed by science and clinical data.

Bribery Allegations Probe In India • Source: Shutterstock

The Indian drugs regulator and Biocon Biologics find themselves in a messy situation after the country’s premier investigating agency said that it was probing allegations of graft pertaining to trial-related permissions for the firm’s insulin aspart.

India’s Central Bureau of Investigation (CBI) said that it had apprehended a joint drugs controller in the act of allegedly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Asia